Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...

Astellas Pharma has entered a strategic partnership with the JFCR to expedite research in translational and clinical oncology ...

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, ...

With an increasing demand for NHS services, technology is being positioned as a critical tool in eliminating inefficiencies ...

Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

According to a factsheet published by the Trump administration, pharmaceuticals are exempted from the tariffs – for now.

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

T2D has been associated with an increased risk of CV mortality and GLP-1RAs are being increasingly used as a T2D and obesity ...